Palisade Bio (STU:7NS0) Debt-to-Asset : 0.01 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Palisade Bio Debt-to-Asset?

Palisade Bio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.12 Mil. Palisade Bio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.05 Mil. Palisade Bio's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was €11.64 Mil. Palisade Bio's debt to asset for the quarter that ended in Mar. 2024 was 0.01.

Palisade Bio Debt-to-Asset Historical Data

The historical data trend for Palisade Bio's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Palisade Bio Debt-to-Asset Chart

Palisade Bio Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

0.47

0.02

0.03

Palisade Bio Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial											0.02	0.04	0.03	0.03	0.01

Competitive Comparison of Palisade Bio's Debt-to-Asset

For the Biotechnology subindustry, Palisade Bio's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Palisade Bio's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Palisade Bio's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Palisade Bio's Debt-to-Asset falls into.

Palisade Bio Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Palisade Bio's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.256	+	0.083)	/	12.886
	=	0.03

Palisade Bio's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.115	+	0.053)	/	11.64
	=	0.01

Palisade Bio (STU:7NS0) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Palisade Bio Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Palisade Bio's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Palisade Bio (STU:7NS0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Palisade Bio Inc (STU:7NS0) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

PALI:USA 7NS:Germany

Address

5800 Armada Drive, Suite 2A, Carlsbad, CA, USA, 92008

Website

https://www.palisadebio.com

Palisade Bio Inc is a clinical-stage biopharma company. It is advancing oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio's innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery.

Palisade Bio (STU:7NS0) Headlines

No Headlines